Skip to main content
Fig. 2 | World Journal of Surgical Oncology

Fig. 2

From: SUVmax reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma

Fig. 2

Kaplan-Meier survival curves showing OS (a), DSS (b), and RFS (c) according to the SUVmax reduction rate in the non-pCR group. Patients with SUVmax reduction rates of 60% or more in the primary tumor are indicated by solid lines (n=44); those with SUVmax reduction rates of less than 60% in the primary tumor are indicated by dotted-dashed lines (n=23)

Back to article page